CAP-IT
banner
ncicapit.bsky.social
CAP-IT
@ncicapit.bsky.social
Official Account of the National Cancer Institute Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Network.
www.ncicapit.org
Pinned
The NCI CAP-IT program discovers and advances targeted agents for cancer prevention by leveraging precancer biology insights. It streamlines development through in vitro, in vivo, and clinical pipelines to accelerate prevention strategies.
Learn more: www.ncicapit.org
At today’s #CAPIT Bioinformatics & Computational Biology WG meeting, Dr. Chi Zhang of University of Nebraska - Lincoln presented his work on AI-powered image feature extraction and data synthesis in pancreatic cancer.
October 28, 2025 at 4:32 PM
The latest CAP-IT Newsletter is out!
It features highlights and reports from the July 2025 CAP-IT Summit, along with updates on network progress:
indd.adobe.com/view/32541c2...
September 15, 2025 at 5:23 PM
New Tools and Resources from the NCI Data Sharing Hub , now added to the CAP-IT Shared Resources Catalog. Check it out and all NCI/NIH Shared resources at the link below:
ncicapit.org/en/resources...
NCI CAP-IT
ncicapit.org
August 7, 2025 at 3:57 PM
Reposted by CAP-IT
The amazing @ptorresayuso.bsky.social from #FoxChaseCancerCenter and #TempleUniversity presenting his exciting research at the @ncicapit.bsky.social summit
July 24, 2025 at 7:33 PM
Reposted by CAP-IT
The 2025 Annual @ncicapit.bsky.social Summit is #Outofthisworld good!!! The plenary speaker #EvaSzabo, the keynote presentation by #RafiAhmed followed by AI guru #ChanghueiYang & #force ‘s #SueFredman & panelist for #EmergingTechnologies lead by the amazing #ShannonHughes were extraordinary!!!
a poster that says out of this world
ALT: a poster that says out of this world
media.tenor.com
July 24, 2025 at 6:59 PM
Don't wait - register now for the CAP-IT Virtual Annual Summit on July 24, 2025!
Open to the public with exciting talks on cancer prevention and interception.
🔗 Register: tinyurl.run/M3wsBV
ℹ️ Info: ncicapit.org
📧 CAP-IT@nih.gov
#CancerPrevention #NCICAPIT
July 11, 2025 at 3:27 PM
A personalized neoantigen vaccine + Montanide/poly-ICLC/ipilimumab reshapes the T cell landscape in melanoma patients:
- Strong CD8+ responses
- TCR repertoires expanded beyond anti–PD-1
- Vaccine-specific TILs identified post-treatment

www.cell.com/cell/abstrac...?
#Neoantigen #Melanoma #Tcells
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma
A personalized neoantigen peptide vaccine formulated with Montanide plus poly-ICLC and administered with local ipilimumab plus systemic nivolumab induces robust neoepitope-specific T cell responses an...
www.cell.com
July 10, 2025 at 7:33 PM
Reposted by CAP-IT
We have a great lineup of events this summer, we hope you can join us!
July 9, 2025 at 8:11 PM
New in @cellcellpress.bsky.social : Exercise boosts immune checkpoint inhibitor (ICI) efficacy in #Melanoma via microbiota-derived formate, which enhances CD8⁺ T cell immunity through Nrf2 activation.

cell.com/cell/abstrac...
#Immunotherapy #Microbiome #CancerResearch
Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy
Exercise enhances antitumor immunity and immunotherapy effectiveness by increasing microbiota-derived formate, which boosts CD8 T cell function and may serve as a biomarker of melanoma suppression.
cell.com
July 9, 2025 at 8:20 PM
New in @thelancet.com : A comprehensive review on cancer vaccines and their role in shaping the future of immunotherapy.
Read here:
www.thelancet.com/journals/lan...
Cancer vaccines and the future of immunotherapy
Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by pro...
www.thelancet.com
June 18, 2025 at 1:41 PM
Reposted by CAP-IT
New @thelancet.com - Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #OncSky
June 14, 2025 at 3:40 PM
New study in Cell: HIF upregulates endogenous retroviruses in clear cell kidney cancer, generating tumor-specific antigens. ERV-targeting T cells show promise for immunotherapy and HIF stabilizers may unlock similar responses in other tumors. #CAPITPublication
pubmed.ncbi.nlm.nih.gov/40023154/
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy - PubMed
Clear cell renal cell carcinoma (ccRCC), despite having a low mutational burden, is considered immunogenic because it occasionally undergoes spontaneous regressions and often responds to immunotherapi...
pubmed.ncbi.nlm.nih.gov
June 17, 2025 at 2:32 PM
We’re excited to announce that the CAP-IT Virtual Annual Summit will be held on July 24, 2025!
Register here:
docs.google.com/forms/d/e/1F...

For more information, visit : ncicapit.org or email: CAP-IT@nih.gov #CancerPrevention #NCICAPIT
Registration for the NCI CAP-IT Annual Summit: July 24, 2025
The upcoming NCI CAP-IT Summit is set to convene a diverse mix of participants, including senior leaders, experts, and emerging talents such as junior investigators and trainees, all dedicated to the ...
docs.google.com
June 12, 2025 at 5:40 PM
Reposted by CAP-IT
REVIEW 🚨

Cancer prevention vaccines have reduced cancer-related mortalities, yet therapeutic cancer vaccine development + clinical translation continue to face challenges. Here, Zaidi, Jaffee & Yarchoan summarize this & highlight advances in the field.

📖 👇
Recent advances in therapeutic cancer vaccines - Nature Reviews Cancer
Cancer prevention vaccines have reduced cancer-related mortalities, yet therapeutic cancer vaccine development and clinical translation continues to face challenges. Here, Zaidi, Jaffee and Yarchoan summarize the failures of cancer vaccines of the past, to highlight recent advancements in the field.
bit.ly
May 22, 2025 at 2:17 PM
Reposted by CAP-IT
Online Now: Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception
Zhu et al. reveal coordinated interplay between innate and adaptive immunity in the transition from precancer to invasive lung cancer. TIM-3 upregulation peaks at precancer stage and its blockade enhances anti-tumor immunity while inhibiting lung precancer progression, suggesting TIM-3 as a potential target for lung precancer interception.
dlvr.it
May 8, 2025 at 6:51 PM
🚨 The 2025 #CAPITSummit is coming!
🗓️ Agenda is live & public registration is now open!
🔗 Explore the program & sign up today via the CAP-IT web portal:
ncicapit.org/en/cap-it-su...
NCI CAP-IT
For conference-related questions, please contact:
ncicapit.org
May 5, 2025 at 6:19 PM
May is Brain Tumor Awareness Month. Here's what you should know about the brain and brain tumors.
May 2, 2025 at 7:30 PM
We’re excited to announce that the CAP-IT Virtual Annual Summit will be held on July 24, 2025!

Register here by May 16, 2025: docs.google.com/forms/d/e/1F...

For more information please visit : NCICAPIT.org or email: CAP-IT@nih.gov

#CancerPrevention #NCICAPIT
Registration for the NCI CAP-IT Annual Summit: July 24, 2025
The upcoming NCI CAP-IT Summit is set to convene a diverse mix of participants, including senior leaders, experts, and emerging talents such as junior investigators and trainees, all dedicated to the ...
docs.google.com
April 28, 2025 at 6:47 PM
🚨 New #JITC article: Researchers uncover frameshift-derived neopeptides in Lynch syndrome—opening doors to innovative cancer prevention strategies.
🔬 Read more: bit.ly/3EiJBUN
Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies
Background Lynch syndrome (LS), caused by germline pathogenic variants in the mismatch repair genes, leads to high rates of frameshift-derived neopeptide (FSDN) expression due to microsatellite instab...
bit.ly
April 24, 2025 at 7:23 PM
Sometimes cancer returns years after treatment—often having spread. Researchers suspect dormant cancer cells and their interactions with the immune system play a key role in when and how this happens.
www.cancer.gov/news-events/...
How Do Dormant Cancer Cells Become Metastases?
The interplay between dormant cancer cells and components of the immune system appears to heavily influence if cancer later returns as metastatic disease.
www.cancer.gov
April 24, 2025 at 7:14 PM